Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- S-1 IPO registration
- 2.1 EX-2.1
- 2.2 EX-2.2
- 2.3 EX-2.3
- 3.1 EX-3.1
- 3.2 EX-3.2
- 4.1 EX-4.1_1
- 4.1 EX-4.1_2
- 4.1 EX-4.1_3
- 4.1 EX-4.1_4
- 4.2 EX-4.2
- 4.2 EX-4.2_1
- 4.3 EX-4.3
- 10.1 EX-10.1
- 10.2 EX-10.2
- 10.3 EX-10.3
- 10.4 EX-10.4
- 10.6 EX-10.6
- 10.11 EX-10.11
- 10.12 EX-10.12
- 10.13 EX-10.13
- 10.14 EX-10.14
- 10.15 EX-10.15
- 10.16 EX-10.16
- 10.17 EX-10.17
- 21.1 EX-21.1
- 22.1 EX-22.1
- 23.1 EX-23.1
- EX-FILING FEES Ex-filing Fees
Associated filings
- 11 Sep 24 8-K 1 Endo Investor Presentation September 2024
- 29 Aug 24 424B3 Prospectus supplement
- 2024 Q2 10-Q Quarterly report
- 27 Aug 24 424B3 Prospectus supplement
- 27 Aug 24 8-K Endo Announces Ceo Transition
- 27 Aug 24 8-K Endo Reports Second-quarter 2024 Financial Results
- 1 Aug 24 EFFECT Notice of effectiveness
- 31 Jul 24 424B3 Prospectus supplement
- 26 Jul 24 S-1/A IPO registration (amended)
-
12 Jul 24 S-1 IPO registration
NDOI similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the use in this Registration Statement on Form S-1 of Endo, Inc. of our report dated March 6, 2024 relating to the financial statements and financial statement schedule of Endo International plc, which appears in this Registration Statement. We also consent to the reference to us under the heading “Experts” in such Registration Statement.
/s/ PricewaterhouseCoopers LLP
Philadelphia, Pennsylvania
July 12, 2024